Previous Article | Next Article 
Journal of Virology, August 2001, p. 6874-6883, Vol. 75, No. 15
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.15.6874-6883.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Characterization of Nuclear RNases That Cleave
Hepatitis B Virus RNA near the La Protein Binding Site
Tilman
Heise,1,2,*
Luca G.
Guidotti,1 and
Francis V.
Chisari1
Department of Molecular and Experimental
Medicine, The Scripps Research Institute, La Jolla, California
92037,1 and Heinrich-Pette-Institut
für Experimentelle Virologie und Immunologie,
Universität Hamburg, D-20251 Hamburg,
Germany2
Received 27 February 2001/Accepted 4 May 2001
 |
ABSTRACT |
Hepatitis B virus (HBV) RNA is downregulated by inflammatory
cytokines induced in the liver by adoptively transferred HBV-specific cytotoxic T lymphocytes (CTLs) and during murine cytomegalovirus (MCMV)
infections of the livers of HBV transgenic mice. The disappearance of
HBV RNA is tightly associated with the cytokine-induced proteolytic cleavage of a previously defined HBV RNA-binding protein known as La
autoantigen. La binds to a predicted stem-loop structure at the 5' end
of the posttranscriptional regulatory element of HBV RNA between
nucleotides 1243 and 1333. In the present study, we searched for
nuclear RNase activities that might be involved in HBV RNA decay.
Nuclear extracts derived from control livers and CTL-injected and
MCMV-infected livers were analyzed for the ability to cleave HBV RNA.
Endonucleolytic activity that cleaved HBV RNA at positions 1269 to 1270 and 1271 to 1272, immediately 5' of the stem-loop bound by the La
protein (positions 1272 to 1293), was detected. Furthermore, we provide
evidence that the cytokine-dependent downregulation of HBV RNA
following MCMV infection is temporally associated with the upregulation
of the endonucleolytic activity herein described. Collectively, these
results suggest a model in which the steady-state HBV RNA content is
controlled by the stabilizing influence of La and the destabilizing
influence of nuclear RNase activities.
 |
INTRODUCTION |
The hepatitis B virus (HBV) is a
noncytopathic, hepatotropic virus with a 3.2-kb circular DNA genome
that encodes four overlapping 3.5-, 2.4-, 2.1-, and 0.7-kb unspliced
messages that terminate at a common polyadenylation site
(45). Because HBV is not infectious in tissue culture,
except for primary hepatocytes or for genetically or immunologically
undefined animals, the development of an HBV transgenic mouse model was
very useful to define the host-virus interactions involved in virus
clearance and disease pathogenesis (2, 10, 11, 22, 23, 25,
37). Using that model, it has been shown that cytotoxic T
lymphocytes (CTLs) inhibit HBV gene expression and replication
noncytopathically at the posttranscriptional level (24,
49) by secreting gamma interferon (IFN-
) and tumor necrosis
factor alpha (TNF-
) upon antigen recognition (20). Consistent with these results, hepatocellular HBV gene expression and
replication are also downregulated noncytopathically by inflammatory cytokines produced during lymphocytic choriomeningitis virus-induced (21) and murine cytomegalovirus (MCMV)-induced
(8) hepatitis in these animals. The intracellular
mechanism(s) whereby the CTL-induced inflammatory cytokines
posttranscriptionally destabilize HBV RNA remains to be determined.
RNA-protein interactions play an important role in the regulation
of pre-mRNA processing (32, 47, 50), nuclear export (19), and stabilization and destabilization (14, 42,
48) of mRNAs. In the systems studied thus far, cellular
RNA-binding proteins and RNases influence transcript stability by
interacting with sequences and/or structural elements in the RNA. In
Saccharomyces cerevisiae, several different pathways
are responsible for mRNA decay, including deadenlyation-dependent and
-independent decapping, 5'-to-3' and 3'-to-5' degradation by
exoribonucleases, and endonucleolytic cleavage within the mRNA
(14). Less is known about the cellular RNases responsible
for mRNA degradation in vertebrates, although some vertebrate RNases
have been characterized in detail (4, 7, 12, 15, 33, 39, 43,
53). A good example of the coordinated action of RNA-binding
proteins, cis-acting RNA elements, and endoribonucleases is
provided by the posttranscriptional control of transferrin receptor
(TFR) mRNA. The interaction of an iron response element in the TFR mRNA
with a cellular iron response element-binding protein
(36), whose binding activity is induced by low cellular
iron concentration (30) and phosphorylation (17), protects the TFR mRNA from endonucleolytic cleavage
(3).
Recently we identified the La autoantigen (p45) and La fragments (p39
and p26) as HBV RNA-binding proteins, which bind to a predicted
stem-loop structure located between nucleotides (nt) 1243 and 1333 of
HBV RNA (26, 27), numbering according Galibert et al.
(18). The presence of full-length La protein correlated directly with the presence of HBV RNA, detectable when the viral RNA
was abundant and disappearing when the RNA degradation was posttranscriptionally induced in response to IFN-
and TNF-
(26). In contrast, p26 was inversely related to HBV RNA,
detectable only when the viral RNA disappeared following cytokine
induction by adoptively transferred HBV-specific CTLs, after MCMV and
lymphocytic choriomeningitis virus infection (26). If p45
actually stabilizes HBV mRNA, it might do so by protecting it against
RNase-mediated degradation at a neighboring cleavage site. To test this
hypothesis, we developed an RNase activity assay (RAA) and analyzed
liver nuclear extracts for RNases able to degrade (i) HBV
oligoribonucleotides, (ii) in vitro-transcribed HBV transcripts, or
(iii) full-length HBV RNA prepared from the livers of HBV transgenic mice.
In the present report, we describe the identification of hepatic RNase
activities able to cleave all three of these HBV RNA substrates in a
site-specific manner. In addition, we show that these activities are
transiently upregulated in the livers of HBV transgenic mice when p45
and HBV RNA disappear and p26 appears following the induction of
IFN-
and TNF-
. These results suggest that an interplay between
the potential destabilizing activity of these RNases and the potential
stabilizing effect of the La protein regulates hepatic HBV RNA content
in this model.
 |
MATERIALS AND METHODS |
HBV transgenic mice.
The HBV transgenic mouse lineages
Tg(HBV 1.3 genome)Chi32 (designated 1.3.32) and Tg(HBV 1.3 genome)Chi46 (designated 1.3.46) used in this study have been described
previously (25). Lineages 1.3.32 and 1.3.46 express
all of the HBV transcripts under the control of their respective
promoters and replicate HBV at high levels in the liver and kidney
without any evidence of cytopathology (25). Mice were
matched for age (8 to 10 weeks), sex (male), and serum hepatitis B e
antigen (HBeAg) concentration using a commercially available
solid-phase radioimmunassay (Sorin Biomedica, Saluggia, Italy).
HBsAg-specific CTLs.
Ld-restricted,
CD3+ CD4
CD8+ hepatitis B surface antigen (HBsAg)-specific
CTL clones that recognize an epitope located between residues 28 and 39 of HBsAg (HBsAg28-29) and secrete IFN-
and TNF-
upon antigen
recognition (20) were used in these studies. In all
experiments, 107 CTLs were injected intravenously
into transgenic mice 5 days after in vitro stimulation with irradiated
P815 cells that stably express the HBV large envelope protein
(2). CTL-induced liver disease was monitored by measuring
serum alanine aminotransaminase levels at various time points after
CTL injection. Liver tissue obtained at autopsy was either processed
for histological analysis or snap-frozen for subsequent molecular analyses.
MCMV infection.
The Smith strain of MCMV (ATCC VR-194;
American Type Culture Collection, Manassas, Va.) was used in this
study. Lineage 1.3.32 mice were injected intraperitoneally with 5 × 104 PFU of MCMV (8) and
sacrificed at various time points thereafter. Livers were harvested,
snap-frozen in liquid nitrogen, and stored at
80°C for subsequent
molecular analysis as previously described (8).
RNA analyses.
Snap-frozen (liquid nitrogen) liver tissues
were mechanically pulverized, and total genomic RNA was isolated for
Northern blot analyses exactly as previously described (24,
25).
Preparation of liver nuclear and cytosolic extracts from HBV
transgenic mice.
Frozen liver tissue (0.2 to 0.5 g) was
thawed and homogenized in a fivefold volume of ice-cold homogenization
buffer containing 10 mM Tris-HCl (pH 7.4), 10 mM NaCl, 2.5 mM
MgCl2, 1 mM EDTA (buffer A) containing 0.5 mM
dithiothreitol (DTT), and 1/25 volume of proteinase inhibitor mixture
(Boehringer Mannheim, Indianapolis, Ind.) by five strokes in a glass
homogenizer with a loose-fitting motor-driven (50 rpm) Teflon pestle.
The homogenate was centrifuged at 2,000 × g for 20 min, and the resulting supernatant was stored at
80°C. The pellet
was resuspended in 6 ml of buffer A containing 0.88 M sucrose (buffer
B), loaded onto a 7-ml cushion of buffer B, and centrifuged at
10,000 × g for 30 min. The supernatant was discarded,
and the pellet was dissolved in 5 ml of buffer A containing 2.0 M
sucrose (buffer C). The slurry was loaded onto a 7-ml cushion of buffer
C and centrifuged at 180,000 × g for 70 min. The
supernatant was discarded, and the nuclei were resuspended in 100 µl
of storage buffer containing 20 mM Tris-HCl (pH 8.0), 75 mM NaCl, 2.5 mM MgCl2, 0.5 mM EDTA, 50% glycerol, 0.5 mM DTT,
and 1/10 volume of proteinase inhibitor mixture (Boehringer Mannheim).
Nuclei were counted by light microscopy and lysed by adding 5× lysis buffer containing 100 mM Tris-HCl (pH 8.0), 2.1 M NaCl, 7.5 mM MgCl2, 1.0 mM EDTA, and 25% glycerol to a final
concentration of 33 mM Tris-HCl (pH 8.0), 420 mM NaCl, 1.5 mM
MgCl2, 0.2 mM EDTA, 5% glycerol, 0.5 mM DTT, and
1/10 volume of proteinase inhibitor mixture (Boehringer Mannheim). The
viscous lysate was transferred into dialysis tubes (molecular weight
cutoff, 6,000 to 8,000) (Spectro/Por; Spectrum Companies, Gardena,
Calif.) and dialyzed three times against 500 ml of dialysis buffer F
containing 10 mM Tris-HCl (pH 7.4), 100 mM NaCl, 3 mM
MgCl2, 0.5 mM EDTA, 10% glycerol, 0.5 mM DTT,
and proteinase inhibitor mixture (Boehringer Mannheim). The dialyzed
nuclear extract was cleared by centrifugation for 10 min at 24,000 × g, and the protein content was determined by the Bradford
dye-binding procedure, with a commercial kit (Bio-Rad Laboratories,
Hercules, Calif.).
In vitro transcription and oligoribonucleotides.
A plasmid
containing the entire HBV genome (ayw subtype) was used for
the production of DNA templates for generation of HBV transcripts. Two
primers were used. Primer 1 (5'-CCATCGATTAATACGACTCACTATAG-3') contained a restriction site for ClaI (shown in italics),
the T7 RNA polymerase promoter sequence (shown in boldface), and the sense HBV ayw DNA sequences (18) spanning nt
1243 to 1261 (5'-GAACCTTTTCGGCTCCTCT-3'). Primer 2 contained
antisense HBV sequences from nt 1312 to 1333 (5'-GTCCCGATAATGTTTGCTCCAG-3') (RNA.B). PCRs for HBV
templates were produced with 1 ng of plasmid, and the mixture contained 80 pmol of each primer in 1× PCR buffer; 0.2 mM (each) GTP,
ATP, TTP, and CTP; and 2.5 U of Taq DNA polymerase
(Boehringer Mannheim). PCR was performed as follows: 5 min at 95°C;
followed by 35 cycles of 1 min at 95°C, 1 min at 56°C, and 1 min at
72°C; and finally 1 cycle for 5 min at 72°C. The PCR
products were purified by size exclusion with a commercial kit (PCR
Purification kit; Boehringer Mannheim), ethanol precipitated, and used
as templates to generate transcripts. Transcription reactions were
carried out with 0.5 to 1.0 µg of PCR product in a final volume of 20 µl in transcription buffer (Promega, Madison, Wis.) containing 0.31 mM ATP, CTP, and GTP; 7.5 mM [
-32P]UTP (800 Ci/mmol) (NEN, Boston, Mass.); 5 mM DTT; and 20 U of RNasin (Promega).
The reaction was started by the addition of 20 U of T7 RNA polymerase
(Promega). After incubation for 45 min at 37°C, another 20 U of T7
RNA polymerase was added to the mixture, and the reaction was continued
for 45 min at 37°C. The reaction was terminated by the addition of 10 µg of yeast tRNA and 1 U of DNase I (Promega) and incubation for 15 min at 37°C. After phenol-chloroform extraction and ethanol
precipitation, transcripts were dissolved in 10 mM Tris-HCl (pH
7.4)-diethyl pyrocarbonate (DEPC)-treated water.
RNA.E and RNA.F are synthetic oligoribonucleotides spanning the HBV
sequence at nt 1243 to 1281 (RNA.E;
5'-GAACCUUUUCGGCUCCUCUGCCGAUCCAUACUGCGGAAC-3') and nt 1243 to 1271 (RNA.F; 5'-GAACCUUUUCGGCUCCUCUGCCGAUCCAU-3'), produced by Oligos Etc., Wilsonville, Oreg.
UV cross-linking (UV-C) experiments.
Standard binding
reactions were carried out with a final volume of 40 µl with 5 µg
of total nuclear protein and 40 fmol of the
32P-labeled transcripts in binding buffer
containing 10 mM Tris-HCl (pH 7.4), 3 mM MgCl2,
1.5 mM EDTA, 450 mM NaCl, 0.01% Triton X-100, 20 µg of yeast tRNA,
and 6 µg of heparin, incubated for 20 min at room temperature.
The reaction mixtures were incubated on ice, irradiated for 10 min with
UV light (254 nm) with a Stratalinker (Stratagene, La Jolla, Calif.)
approximately 3 cm from the bulbs, and then digested with 40 µg of
RNase A and 100 U of RNase T1 for 45 min at
37°C. Forty microliters of sodium dodceyl sulfate (SDS) sample buffer
(2% SDS, 5% mercaptoethanol, 63 mM Tris-HCl [pH 6.8], 10%
glycerol, and 0.01% bromphenol blue) was added, and samples
were boiled for 5 min, placed on ice, and resolved on an SDS-12.5%
polyacrylamide gel electrophoresis (PAGE) gel. After
electrophoresis, the gels were stained with Coomassie blue, destained,
dried, and exposed to Biomax (Kodak, Rochester, N.Y.) overnight at
80°C.
RAA.
Standard RAA reactions were carried out with a final
volume of 40 µl with 1 µg of total nuclear protein and 50,000 to
150,000 cpm of the 5' 32P-labeled HBV
oligoribonucleotide E (RNA.E), 40 fmol of unlabeled in vitro transcript
B (RNA.B), or 5 µg of total liver RNA prepared from HBV transgenic
mice in a reaction buffer containing 10 mM Tris-HCl (pH 7.4), 3 mM
MgCl2, 1.5 mM EDTA, 300 mM NaCl, and 0.01% Triton X-100 for 20 min at 37°C. Reactions were stopped by the addition of 150 µl of 10 mM Tris-HCl (pH 7.4), 20 µl of 3 M Na acetyl (Ac) (pH 5.2), and 10 µg of yeast tRNA. Proteins were
extracted by the addition of 100 µl of phenol-chloroform-isoamyl
alcohol (1:1:29). Samples were vortexed and centrifuged at
maximal speed for 4 min in a tabletop centrifuge (23,000 × g). Two hundred microliters of supernatant was transferred
to a new tube and extracted with 100 µl of chloroform. After
centrifugation as described above, supernatants were transferred into a
new tube, and 600 µl of ethanol (absolute) was added. Samples were
mixed, and RNA was precipitated at maximum speed for 15 min at room
temperature in a tabletop centrifuge (23,000 × g).
Pellets were washed with 100 µl of 80% ethanol and vacuum dried.
Pellets were used for primer extension or were resuspended in 10 µl
of loading buffer (containing 80% formamide, 1× TBE [45 mM Tris, 45 mM boric acid, 1 mM EDTA, pH 8.5], and 0.01% bromphenol blue)
and xylene xyanol, loaded, and resolved on a 10% denaturating PAGE
gel. After electrophoresis, the gels were transferred to filter paper,
dried under vacuum at 80°C for 2 h, and exposed to Biomax
(Kodak) overnight at
80°C or analyzed by phosphorimaging.
5' Labeling and gel purification.
Standard labeling
reactions were carried out as described in the manufacturer's
instructions (Ambion, Austin, Tex.). Briefly, 5 µl of nuclease-free
water, 1 µl of oligonucleotide (10 pmol), 1 µl of
[
-32P]ATP (NEN, Boston, Mass.), 2 µl of
5× forward reaction buffer, and 1 µl of T4 polynucleotide kinase (1 U/µl) were incubated for 30 min at 37°C. After the addition of 10 µl of loading buffer, samples were heated for 10 min at 68°C,
cooled on ice, and resolved on a 10% 1.5-mm-thick denaturing PAGE gel.
After electrophoresis, the gels were covered with plastic wrap, exposed
for 3 min to Kodak Biomax, and developed, and the full-length bands
were cut out. The labeled oligonucelotides were eluted in elution
buffer containing 20 mM Tris-HCl ( pH 7.4), 300 mM NaCl, and 0.5 mM
EDTA for 1 h at 56°C. The elution buffer was replaced, and after
the addition of new elution buffer the extraction was continued for 1 h at 56°C. Both eluates were combined, and 1/10 volume of the 3 M NaAc (pH 5.2), 10 µg of tRNA, and 2.5 volumes of ethanol
(absolute) were added. Labeled oligonucleotides were recovered by
precipitation and resolved in nuclease-free water, and aliquots were counted.
Primer extension.
RNA pellets obtained from the RAA reaction
mixtures were washed with 70% ethanol-DEPC-treated water, dried, and
resuspended in 7 µl of DEPC-treated sterile
H2O. Two microliters of 5× annealing buffer (250 mM Tris-HCl [pH 8.3], 2.7 M KCl, 5 mM EDTA) was added to the RNA
along with 1 µl of 5' 32P-labeled HBV-specific
primer (approximately 2 × 105 cpm
containing antisense HBV sequences from nt 1312 to 1333 [5'-GTCCCGATAATGTTTGCTCCAG-3']). RNA was denatured by
heating at 70°C for 10 min and annealed to the primer by 56°C for
either 2 h or overnight. For extension reactions, the 10 µl of
annealing reaction mixture was brought to 40 µl containing a 0.7 mM
final concentration of dATP, dCTP, dGTP and dTTP; 50 mM Tris-HCl
(pH 8.3); 5.0 mM MgCl2; 135 mM KCl; 0.25 mM EDTA;
50 ng of actinomycin D/µl; and 10 U of SuperScript reverse
transcriptase (Gibco BRL)/µl. The extension reaction
mixtures were incubated at 37°C for 3 h. Reactions were
terminated with 170 µl of precipitation buffer (370 mM NaAc, 10 mM
Tris-HCl [pH 7.4] in DEPC-treated H2O, 0.5 µg
of tRNA/µl), extracted with phenol-chloroform-isoamyl alcohol
(24:25:1), ethanol precipitated, and subjected to electrophoresis with
12% polyacrylamide sequencing gels.
 |
RESULTS |
Identification of a distinct cleavage event within the in vitro
transcript HBV RNA.B.
Recently, a tight correlation was found
between the cytokine-mediated downregulation of HBV RNA and the
disappearance of the full-length HBV RNA-binding protein La, coinciding
with the appearance of a smaller La fragment (26). The La
binding site was mapped to a computer-predicted stem-loop structure
(Fig. 1) (27). It was
concluded that this interaction may determine the stability of HBV RNA
and that disruption of this interplay allows RNases to attack HBV RNA,
thereby accelerating the decay of HBV RNA.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 1.
Predicted secondary structure of HBV in vitro transcript
RNA.B bound by the La protein. The secondary structure of the
91-nt-long in vitro transcript RNA.B was calculated with the MFOLD
program, version 3 (http://mfold2.wustl.edu/~mfold/rna/form1.cgi). The free
energy of the structure was calculated to be 25.0 kcal/mol. The
stem-loop 2 represents the La binding site. Arrows indicate the 3' ends
of synthetic oligoribonucleotides RNA.E and RNA.F and the identified
cleavage sites at positions 1269 to 1270 and 1271 to 1272. The
positions for all RNAs are shown according to the HBV
ayw subtype sequence.
|
|
To identify a potential cleavage site within the HBV RNA, we developed
an RAA with different HBV RNAs as substrates and nuclear
extracts
prepared from untreated, MCMV-infected, or CTL-injected
HBV transgenic
mouse liver as a source for RNases. First, we asked
whether distinct
HBV RNA cleavage products could be detected by
primer extension after
incubation of HBV RNA.B with various nuclear
extracts. Following
incubation of the unlabeled in vitro transcript
RNA.B (Fig.
1) with
nuclear extracts, remaining RNA was phenol-chloroform
extracted,
precipitated, and subsequently analyzed by primer extension
analysis to
detect potential 3' cleavage products (3'-CPs). The
5'
32P-labeled antisense primer was located at the
3' end of RNA.B,
spanning nt 1312 to 1333. As shown in Fig.
2A, two 3'-CPs (3'-CP1
and -2) were
detected after incubation of RNA.B with nuclear extracts
prepared from
CTL-injected or untreated HBV transgenic mice. The
background bands
probably represent products of nonspecific degradation
or pausing sites
of the reverse transcriptase. Importantly, the
full-length primer
extension product was reduced in a time-dependent
manner, predominantly
with the CTL extracts (Fig.
2, lanes 2 and
3) compared to extracts from
untreated mice (lanes 5 and 6). No
obvious difference was seen in the
amount of 3'-CPs produced by
both nuclear extracts. This could be
explained by assuming that
the cleavage products had already reached a
steady state between
synthesis and further degradation. Addition of 40 U of RNase inhibitor
(RNasin) to the RAA reduced the signal for 3'-CP2
and prevented
the overall degradation of the input RNA (Fig.
2, compare
lanes
3 and 4 and 6 and 7). These data indicate that the input RNA was
cleaved at two positions and that RNA degradation was much more
efficient with nuclear extracts prepared 5 days after CTL injection,
corresponding to reduced levels of viral RNA and cleavage of La
protein
(
25) in the livers of HBV transgenic mice
(
24). Additionally,
the strong reduction of 3'-CP2 in the
presence of RNasin could
be explained if we assume that after an
initial endoribonucleolytic
cleavage of RNA.B (RNasin-resistant
3'-CP1), additional nucleotides
were removed by nonspecific
5'-to-3' exoribonucleases (RNasin-sensitive
3'-CP2). Also, it remains
to be understood how stable the 3'-CP
intermediates are, to understand
whether the strong degradation
by CTL extracts was due to a higher
cleavage rate or activation
of additional RNases or if the cleavage
site was more accessible
for the RNase because the La protein was
processed.

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 2.
RNA.B and RNA.E are cleaved by RNases present in nuclear
extracts prepared from HBV transgenic mice. (A) Unlabeled RNA.B was
incubated for 30 or 60 min with or without 1 µg of nuclear extracts
(NE) prepared from the livers of HBV transgenic mice, and the cleavage
products were analyzed by primer extension as described in Materials
and Methods. CTL d5, nuclear extract prepared from the livers of HBV
transgenic mice sacrificed on day 5 after CTL administration; Con,
nuclear extract prepared from the liver of untreated transgenic mice.
RNase inhibitor (40 U) was included in lanes 4 and 7. 3'-CP1 and -2 are
indicated. (B) 5' 32P-end-labeled RNA.E was incubated for
30 min with nuclear extracts (NE) prepared from untreated HBV
transgenic mice under standard conditions as described for the RAA, and
5'-CPs were detected. 5'-CP1 was inhibited in the presence of an RNase
inhibitor (40 U). RNA was analyzed with a 12% denaturing PAGE gel.
|
|
Next, we asked whether or not the cleavage products were generated by
endoribonucleolytic cleavage. We used the 5'
32P-labeled oligoribonucleotide RNA.E spanning
the 5' part (nt 1243
to 1281) of the RNA.B (nt 1243 to 1333) as a
substrate for RNase
activity present in nuclear extracts derived from
untreated transgenic
mouse liver (Fig.
1). As shown in Fig.
2B, RNA.E
was degraded,
and 5'-CPs were detectable. Addition of 40 U of RNasin
hindered
the appearance of 5'-CP1 (Fig.
2B, lanes 3), suggesting that
this
product may have been generated by an RNasin-sensitive RNase,
while the other product was probably generated by RNasin-insensitive
RNases. Note that after primer extension analysis of degraded
RNA.B,
the shortest 3'-CP (3'-CP2) was reduced in the presence
of RNasin (Fig.
2A, lanes 4 and 7), suggesting that 3'-CP2 and
5'-CP1 were produced by
the same activity. To map the cleavage
sites more accurately, the
shorter 5'
32P-labeled RNA oligoribonucleotide
RNA.F (nt 1243 to 1271; 29 nt)
was used in the RAA (Fig.
1). RNA.F was
cleaved and a 5'-CP similar
in size to the 5'-CP2 observed with RNA.E
was obtained (Fig.
3).
Interestingly,
5'-CP1 was only detectable with RNA.E and not with
RNA.F, indicating
that 5' cleavage site 1 was located a few bases
3' of the 3' end of
RNA.F and that 5' cleavage site 2 was probably
located a few
nucleotides 5' of the 3' end of RNA.F (Fig.
3).
Therefore, it is
concluded that HBV RNA.E was cleaved at nucleotides
between positions
1265 and 1274.

View larger version (71K):
[in this window]
[in a new window]
|
FIG. 3.
Identification of cleavage sites using synthetic
RNA substrates of different lengths. A standard RAA was performed under
conditions described in Materials and Methods. Liver nuclear extracts
(NE) (1 µg) prepared from the livers of untreated HBV transgenic mice
were incubated for 30 min at 37°C with 80,000 cpm of 5'-labeled RNA.E
or RNA.F. RNA was analyzed with a 12% sequencing gel. RNase inhibitor
(40 U) was included in lanes 4 and 8. 5'-CP1 and -2 are indicated.
|
|
To show that the cleavage sites were also recognized in full-length HBV
RNA and to locate the cleavage sites more precisely,
total RNA was
prepared from control HBV transgenic mice and subsequently
analyzed by
RAA and primer extension analysis (Fig.
4). Two 3'-CPs
were detected after
incubation of full-length HBV RNA with nuclear
extracts from livers
obtained 5 days after CTL injection. Importantly,
the signal for 3'-CP2
was again hindered in the presence of RNasin.
The sequencing ladder
produced with the same primer (nt 1312 to
1333) used for the primer
extension analysis revealed the cleavage
sites at position 1269 to 1270 and 1271 to 1272 in the viral RNA.
These positions match very well with
the predicted cleavage positions
extrapolated from the analysis of the
5'-CPs (Fig.
3).

View larger version (96K):
[in this window]
[in a new window]
|
FIG. 4.
HBV RNA is cleaved at positions 1269 to 1270 and 1271 to
1272 by RNase present in nuclear extracts prepared from HBV transgenic
mice. HBV RNA (5 µg) extracted from livers of untreated HBV
transgenic mice was incubated with nuclear extract (1 µg) prepared
from the livers of HBV transgenic mice sacrificed on day 5 after CTL
administration (CTL NE), processed, and subsequently analyzed by primer
extension as described in Materials and Methods. RNase inhibitor (40 U)
was included as indicated. The sequencing ladder was produced with a
plasmid containing HBV DNA as a template and the same 5'
32P-labeled oligonucleotide used for the primer extension
reaction. Reaction products were loaded on the same sequencing gel.
3'-CP1 and -2 are indicated.
|
|
Taken together, precise mapping of 3' cleavage positions 1 and 2 within
full-length HBV RNA and the detection of 5'-CPs most
likely indicates
that HBV RNA was cleaved by an endoribonuclease.
This is further
supported by the observation that the longest
5'-CP and the shortest
3'-CP were reduced in the presence of RNasin.
In addition, evidence was
provided that degradation of RNA.B was
more efficient with nuclear
extracts prepared from CTL-injected
mice.
Next, changes in RNase activity in liver nuclear extracts prepared from
MCMV-infected HBV transgenic mice were monitored.
RNA.E was used as a
substrate because this RNA does not include
the complete sequence
necessary to form the proposed La binding
site and, consequently,
cleavage should be independent of endogenous
La binding to the
substrate. Liver nuclear extracts and total
liver RNA were prepared at
various time points after MCMV infection.
HBV RNA, RNA-binding
proteins, RNase activities, and cytokine
gene expression were
subsequently monitored by Northern blot analysis,
UV-C, RAA, and RNase
protection analysis (RPA), respectively.
As shown in Fig.
5, the disappearance of HBV RNA and p45
coincided
with the appearance of the 5'-CP1 and p26 on day 3 after MCMV
infection, at which time the inflammatory cytokines (IFN-

and
TNF-

) and 2',5'-oligoadenylate synthase (OAS; a marker for
IFN-

/
induction) were strongly induced. These changes were
maintained
through day 7, after which HBV RNA and the cytokines
returned
to baseline levels, followed by the reappearance of p45
coinciding
with the disappearance of p26 and 5'-CPs on day 14. These
results
suggest that at least during the first several days after MCMV
infection the cytokine-associated changes in RNase activity and
RNA-binding proteins contribute to the disappearance of the viral
RNA.
The fact that the RNase activity and the HBV RNA-binding
protein La
take longer to return to baseline than the HBV RNA
suggests that other
events contribute to the reappearance of the
viral RNA. These results
were confirmed by the analysis of liver
nuclear extracts prepared at
various time points after CTL injection
of HBV transgenic mice (T. Heise and F. V. Chisari, unpublished
observation). The very close
relationship between the RNase activity
and the presence of La
proteins, however, suggests that they may
be functionally linked, as is
suggested by the physical proximity
of the RNase cleavage sites and the
La binding site in the viral
RNA (Fig.
1). It is important to point
out, however, that the
increase in RNase activity is independent of the
binding of La
to the predicted stem-loop (nt 1275 to 1291), since RNA.E
(nt
1243 to 1281) does not include the complete sequence necessary
to
form this structure and was unable to compete for La binding
to RNA.B
(
27). Therefore, it is possible that the increase in
RNase
activity reflects other cytokine-inducible events such as
inactivation
of an inhibitor or posttranslational modification
of the RNase. These
results suggest again a correlation between
the changes in RNase
activity and RNA-binding proteins, both of
which may contribute to the
disappearance of the viral RNA.

View larger version (94K):
[in this window]
[in a new window]
|
FIG. 5.
Kinetics of RNA.E cleavage during MCMV infection. HBV
transgenic mice were infected with MCMV, and livers were harvested from
groups of mice sacrificed on day 1 (d1), d3, d5, d7, d14, and d28 after
infection, as indicated. Total hepatic RNA and liver nuclear extracts
were prepared and then analyzed by Northern blotting (NB), UV-C, RAA,
and RPA as described in Materials and Methods. Northern blots were
probed for the expression of HBV RNA, glyceraldehyde-3-phosphate
dehydrogenase mRNA (GAPDH), and 2',5'-OAS mRNA and compared to total
liver RNA prepared from two saline-injected animals. Nuclear extracts
(5 µg) from each mouse were incubated with 40 fmol of in
vitro-transcribed RNA.B, processed, and analyzed by SDS-PAGE. Nuclear
extracts (1 µg) from each mouse were incubated with 80,000 cpm of
RNA.E, processed as described in Materials and Methods, and analyzed
with a 12% sequencing gel. Total RNA (10 µg) from the same livers
was analyzed by RPA for the expression of TNF- and IFN- . The mRNA
encoding the ribosomal protein L32 was used to normalize the amount of
RNA loaded in each lane. 5'-CP1 and -2 are indicated.
|
|
Because the RNase activity increased in parallel with the disappearance
of p45 and the appearance of p26, we asked whether
p45, p39, or p26
displayed RNase activity. Therefore, liver nuclear
extracts prepared
from untreated and CTL-injected mice were mixed,
partially purified as
recently described (
27), and finally subjected
to gel
filtration. The derivative fractions were analyzed for
HBV RNA-binding
and HBV-specific RNase activity by UV-C and RAA,
respectively. As shown
in Fig.
6, the RNase activity responsible
for the production of the 5'-CPs eluted later than the appearance
of
p45, p39, and p26, suggesting that these proteins do not display
RNase
activity. For unknown reasons, little or no p45 was detected
in the gel
filtration fractions (Fig.
6, fractions 16 and 17),
and thus it remains
to be determined whether p45 displays RNase
activity. However, the fact
that the RNase activity increases
as the content of p45 decreases (Fig.
5) makes this possibility
quite unlikely. The RNases responsible for
the 5'-CPs eluted in
fractions 21 and 22, suggesting either that the
same RNase produces
all of the cleavage products or that different
RNases with similar
molecular masses are responsible for the
observed cleavages.

View larger version (60K):
[in this window]
[in a new window]
|
FIG. 6.
p45, p39 and p26 do not display RNase activity. HBV
transgenic mice were injected with saline or 107 CTLs, and
livers were harvested from groups of mice sacrificed on days 3 and 5 and from untreated mice. Liver nuclear extracts were prepared, mixed,
partially purified, and subjected to gel filtration as described
previously (27). Twenty-microliter aliquots of the
indicated gel filtration fractions were analyzed by UV-C (UV) and RAA
as described in Materials and Methods. Gel filtration aliquots were
incubated with 40 fmol of in vitro-transcribed RNA.B, processed, and
analyzed by SDS-PAGE (UV) or subjected to RAA and processed as
described in Materials and Methods. The remaining RNA was analyzed with
a 12% sequencing gel. 5'-CP1 and -2 are indicated.
|
|
Characterization of nuclear endoribonuclease activities in extracts
from control mice.
Additional studies were performed in order to
characterize the RNase activities in more detail; to do so, we studied
the kinetics and temperature dependence of RNase activity. We first
determined the optimal reaction temperature to be 37°C or higher,
while the substrate was only partially cleaved at 23°C and no
cleavage was observed at 4°C (Fig. 7).
Monitoring the cleavage efficiency over time revealed that 5'-CP2 was
produced at the highest rate and that after 80 min almost no further
increase in cleavage products was observed (Fig. 7). At this time, we
do not know whether this reflects a steady state between cleavage and
subsequent degradation of the cleavage intermediates or whether the
enzymes are destroyed or inhibited by the products. We then analyzed
the nature of these RNases and studied the influence of the different
components in standard reaction mixtures. Prior digestion of nuclear
extracts with proteinase K reduced the appearance of 5'-CP1 (Fig.
8A, compare lanes 2 and 3), while little
reduction was observed for 5'-CP2. Furthermore, prior heating of the
nuclear extracts at the indicated temperature for 10 min and subsequent
centrifugation of precipitated denatured proteins revealed that
the activities were quite stable. However, heating the extract at 75 or
95°C partially or completely destroyed the activity, respectively,
indicating a protein-dependent cleavage of RNA.E (Fig. 8B). To measure
the pH dependency of the RNases, the RAA was performed at pH 9.5, 7.4, and 5.2 (Fig. 8A, lanes 4 through 6). Cleavage was almost completely
inhibited at pH 9.5, while 5'-CP1 appeared maximal at pH 7.4 (Fig. 8A,
lanes 4 and 7) and 5'-CP2 was produced maximally at pH 5.2 (Fig. 8A, lane 4). Collectively, these results suggest that the RNases in the
liver nuclear extracts probably consist of one or several proteins.

View larger version (48K):
[in this window]
[in a new window]
|
FIG. 7.
Time and temperature dependencies of RNA.E cleavage. A
standard RAA was performed under conditions described in Materials and
Methods. Liver nuclear extracts (NE) (1 µg) prepared from the livers
of untreated HBV transgenic mice were incubated with 80,000 cpm of
5'-labeled RNA.E and incubated for different periods of time as
indicated or for 20 min at 4, 23, and 37°C. Remaining RNA was
analyzed with a 12% sequencing gel. 5'-CP1 and -2 are indicated.
|
|

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 8.
Dependence of nuclear ribonucleolytic activity on pH,
proteinase K, and temperature. A standard RAA was performed under
conditions described in Materials and Methods. Liver nuclear extracts
(NE) (1 µg) prepared from the liver of untreated HBV transgenic mice
were incubated for 30 min at 37°C with 80,000 cpm of 5'-labeled
RNA.E. Remaining RNA was analyzed with a 12% sequencing gel. (A)
Pretreatment of the extracts with proteinase K (20 µg) was performed
for 30 min at 37°C (lane 3), or cleavage reactions were performed at
pH 5.2, 7.4, or 9.5 (lanes 4, 5, and 6). (B) Nuclear extracts (NE) were
heated at 45, 55, 75, and 95°C for 10 min, cleared by centrifugation,
and subjected to RAA. 5'-CP1 and -2 are indicated.
|
|
In separate experiments (Fig.
9), we
demonstrated that the RNase activities were independent of
MgCl
2 and other divalent ions
(data not shown),
EDTA, and Triton X-100 but were strongly inhibited
at higher sodium
chloride salt concentrations (450 mM) (Fig.
9,
compare lanes 2 and 6).

View larger version (69K):
[in this window]
[in a new window]
|
FIG. 9.
Characteristics of RNA.E cleavage. A standard RAA was
performed under conditions described in Materials and Methods (lanes 1 and 2) with the alterations as indicated (lanes 3 through 7). Liver
nuclear extracts (NE) (1 µg) prepared from the livers of untreated
HBV transgenic mice were incubated for 30 min at 37°C with 100,000 cpm of 5'-labeled RNA.E. Remaining RNA was analyzed with a 12%
sequencing gel. 5'-CP1 and -2 are indicated.
|
|
To determine the chemical nature of the cleavage products, we attempted
to discriminate between a 3'-terminal hydroxyl or
3' phosphate group
(Fig.
10). Therefore, an RAA sample was
separated
on a 10% urea polyacrylamide gel, and the cleavage products
were
eluted, precipitated, and subsequently treated with
phosphodiesterase
(PDE, also known as snake venom). PDE is an
exonuclease selectively
degrading RNA molecules containing a 3'
hydroxyl group but not
a 3' phosphate (
46). In a separate
reaction, 5'-labeled RNA.E
was treated with PDE under the same
conditions. As shown in Fig.
10, PDE was able to degrade the 5'-labeled
substrate RNA.E (compare
lanes 4 and 5) but not the eluted cleavage
products (compare lanes
6 and 7), indicating that the described
activities produce cleavage
products containing 3' phosphate and 5'
hydroxyl groups.

View larger version (48K):
[in this window]
[in a new window]
|
FIG. 10.
Characterization of the 5'-CPs. A standard RAA was
performed with or without RNase inhibitor (lanes 2 and 3) under the
conditions described in Materials and Methods. Liver nuclear extracts
(NE) (1 µg) prepared from the liver of untreated HBV transgenic mice
were incubated for 30 min at 37°C with 100,000 cpm of 5'-labeled
RNA.E. Cleavage products were detected by autoradiography, extracted,
precipitated, and dissolved in 7 µl of DEPC-treated water. 5'-labeled
RNA.E (lane 5) and purified 5'-CPs (lanes 6 and 7) were treated with
PDE (1 µl) for 5 min at room temperature in 20 µl of 100 mM
Tris-HCl (pH 8.0), 100 mM NaCl, and 14 mM MgCl2. The
remaining RNA was extracted and analyzed with a 12% sequencing gel.
|
|
 |
DISCUSSION |
HBV RNA is downregulated by inflammatory cytokines induced in the
liver following the injection of HBsAg-specific CTLs or during
unrelated viral infections that cause hepatitis in HBV transgenic mice
(8, 21-24). During a search for hepatocellular proteins
that mediate the cytokine-induced degradation of HBV RNA, we recently
demonstrated a correlation between the disappearance of the viral RNA
and the appearance of a fragment of the La protein in the mouse liver
following CTL injection or viral infection (26, 27). In
the present study we identified endoribonucleolytic activities that
cleave the viral RNA close to the binding site of the La protein. These
activities were upregulated concurrent with HBV RNA decay and the
appearance of a La protein fragment, suggesting that a functional
correlation may exist between these two parameters and the
endoribonuclease. Several endoribonucleases were recently described,
and in some cases it was shown that the cleavage site can be protected
by RNA-binding proteins, indicating that a regulatory mechanism for
mRNA degradation could be the protection of cleavage sites by protein
factors (3, 7, 13, 53, 54). Recently, the La protein was
described as stabilizing a histone mRNA decay intermediate, indicating
that the La protein prolongs the histone mRNA half-life
(33). That such a mechanism may also be operative in the
cytokine-mediated downregulation of HBV is reasonable to assume,
because the disappearance of HBV RNA coincides with the disappearance
of the full-length La protein which was shown to bind to a specific HBV
RNA structure. In support of this assumption, preliminary data from our
lab suggest that the HBV RNA half-life is reduced when structural
features of the La binding site are changed by mutagenesis (T. Heise
and I. Ehlers, unpublished observations). That 3'- as well as 5'-CPs
were generated by cleavage at the same positions was shown by mapping
of the 3' cleavage sites to positions 1269 to 1270 and 1271 to 1272 and by narrowing down the 5' cleavage sites with substrates of different length. These sites are located immediately upstream of a
computer-predicted stem-loop structure identified as a La binding site
(Fig. 1) (27). In addition, it was shown that detection of
5'-CP1 and 3'-CP2 was reduced in the presence of RNasin, indicating
that the same activity produced the 5'-CP1 and the 3'-CP2.
We observed different cleavage efficiencies in nuclear extracts
prepared from untreated and treated mice. The primer extension analysis
of HBV RNA revealed strong degradation of RNA.B with nuclear extracts
prepared from CTL-injected mice and less-efficient degradation with
nuclear extracts from untreated mice (Fig. 2). Note that the extract
with increased RNase activity was prepared from liver, harvested 5 days
after CTL injection, at a time when HBV RNA levels were reduced and La
was fragmented (26). The coincidence of HBV RNA decay, La
fragmentation, and efficient cleavage of HBV RNA substrates strongly
supports a functional correlation between HBV RNA stability, the
presence of a full-length La protein, and lower levels of
endoribonucleolytic activity. Since the cleavage site is located
immediately 5' to the La binding site, it is possible that La
sterically hinders RNases from accessing the cleavage sites.
The cleavage of the 5'-labeled RNA.E was more pronounced after MCMV
infection (Fig. 5) at time points when HBV RNA was reduced, cytokines
were induced, p45 was absent, and p26 was detectable. The transient
increase in cleavage efficiency suggests that the cleavage might be
independent of the stem-loop and/or the binding of the full-length La
protein to it, indicating an upregulation of these RNase activities.
Furthermore, the estimated molecular mass of less than 26 kDa (Fig. 6)
excludes the possibility that the La protein or the La fragments
detectable by UV-C experiments display the RNase activity detected in
these assays. Therefore, it is assumed that the increase in cleavage
efficiency is due to an upregulation of endoribonucleases by either the
induced expression of the endoribonucleases, their activation by
posttranslational modification, or the inactivation of an inhibitor. An
increase in RNase activity has been reported after herpes simplex virus infection of Vero cells (40), after human immunodeficiency
virus infection of lymphocyte cell lines (1), after
insulin treatment of primary rat hepatocytes (28), and
after estrogen treatment (15, 41). RNase L is activated by
2'-5'-linked oligoadenylates produced after the induction of 2'-5'
oligoadenylate synthetase by IFN or by the appearance of
double-stranded RNAs in cells (16, 34). RNase L is thought
to be part of a host defense mechanism against viral infections.
However, the molecular masses of two RNase L forms in mice were
determined as 40 and 80 kDa (44), which differs
from the apparent molecular mass of the RNases described in our report.
Obviously, until the identity of the endoribonucleolytic activity
described in this study is established and its functional role in the
stabilization or destabilization of HBV RNA can be directly tested, we
must consider the possibility that this endoribonucleolytic activity is
related to known endoribonucleases and that the different cleavage
products are related to different endoribonucleolytic activities.
Comparison of these activities with known endoribonucleases provides
some information about the type of enzymes involved in cleavage. The
activities were found to be partially RNasin resistant and proteinase K
sensitive and partially inactivated at 75°C; the RNA substrate was
cleaved in a time- and temperature-dependent manner (Fig. 7 and
8B). Some other proteins are described to be proteinase K
resistant, like the RNA-binding protein Auf (5) and the
ferritin L chain, which displays also RNA-binding activity (29). Furthermore, the activities were independent of
MgCl2, and the cleavage efficiency was reduced at
high concentrations of NaCl (Fig. 9). These features are most
consistent with the cleavage properties reported for polysomal RNase 1, which is also independent of divalent ions, inhibited at high salt
concentrations, still active after heating at 70°C, and RNasin
resistant, but different in molecular mass (9, 15).
The calculated molecular mass of less than 26 kDa indicates that the
activities described in this report are different from those of
endoribonucleases described cleaving c-myc mRNA (~39 kDa)
(33), albumin mRNA (~60 kDa) (9, 15),
interleukin-2 mRNA (~60 to 70 kDa) (31), and Xihbox2B
mRNA (~120 kDa) (6, 7) and from RNase L (~40 and 80 kDa) (44). The molecular masses for the endonucleolytic
activities involved in the decay of TFR mRNA (3) and
insulin-like growth factor II mRNA (35, 38) are, to our
knowledge, currently undefined. Other endoribonucleases described as
human equivalents of prokaryotic RNA.E with molecular masses of ~65
(55) and 13.3 (12, 52) kDa have been
described. Therefore, the endoribonuclease activity described in
this report appears to be different in molecular mass from all
previously reported endoribonucleases except for ARD-1 (activator of
RNA decay 1) (12).
Another unique feature of the activity described herein is the
production of cleavage products carrying a 3' phosphate group, which
protected the cleavage product against degradation by PDE (Fig. 10).
This observation distinguishes these RNases from the polysomal RNase 1 and ARD-1, because these RNases produced cleavage products with
3' hydroxyl groups (9, 12, 46).
The cleavage position recognized in intact viral RNA prepared from the
liver of HBV transgenic mice was mapped to the sequence 5'-CCA/UA/CU-3'. Although we do not know whether the
surrounding nucleotides or the structural features of the RNA molecule
influence recognition of the cleavage site by the RNase activity
described in this report, some endoribonucleases are known to cleave
their substrates adjacent to an adenosine (3, 4, 9, 38). We do not know yet how selectively the HBV RNA was cleaved by this
endoribonucleolytic activity, and it is possible that the viral RNA was
cleaved at additional positions as described for estrogen-regulated
endoribonucleases involved in the decay of albumin mRNA
(9) and apolipoprotein 2 mRNA (4), which
cleaved the respective mRNA at several positions.
In summary, we have identified a novel endoribonucleolytic activity in
nuclear extracts prepared from normal and especially inflamed
transgenic mouse liver tissue that cleaves HBV RNA in proximity to the
proposed La binding site. The upregulation of this endoribonuclease
activity correlates with the disappearance of p45, the full-length La
protein, and with the degradation of HBV RNA from the liver in response
to CTL injection or MCMV infection. Purification of the
endoribonuclease and more-detailed characterization of the cleavage
site will be necessary to determine the precise mechanisms whereby this
endoribonucleolytic activity regulates the stability of HBV RNA in this model.
 |
ACKNOWLEDGMENTS |
We thank Kazuki Ando and Tetsuya Ishikawa for providing the CTL
clones and Victoria Cavanaugh for the MCMV-infected livers that were
used in these studies. We are also grateful to Hans Will for critical
comments on the manuscript. We thank the Scripps Molecular Biology Core
Facility for the production of oligonucleotides.
This work was supported by NIH grants CA 40489 (F.V.C.) and AI 40696 (L.G.G.) and by Deutsche Forschungsgemeinschaft grant HE 2814/2-1
(T.H.).
 |
FOOTNOTES |
*
Corresponding author. Mailing address:
Heinrich-Pette-Institut für Experimentelle Virologie und
Immunologie, Universität Hamburg, Martinistr. 52, D-20251
Hamburg, Germany. Phone: 49-40-48051-220. Fax: 49-40-48051-222. E-mail:
heise{at}hpi.uni-hamburg.de.
This is manuscript number 1365-MEM from the Scripps Research Institute.
 |
REFERENCES |
| 1.
|
Agy, M. B.,
C. H. Sherbert, and M. G. Katze.
1996.
Development of an in vitro mRNA degradation assay utilizing extracts from HIV-1- and SIV-infected cells.
Virology
217:158-166[CrossRef][Medline].
|
| 2.
|
Ando, K.,
L. G. Guidotti,
A. Cerny,
T. Ishikawa, and F. V. Chisari.
1994.
CTL access to tissue antigen is restricted in vivo.
J. Immunol.
153:482-488[Abstract].
|
| 3.
|
Binder, R.,
J. A. Horowitz,
J. P. Basilion,
D. M. Koeller,
R. D. Klausner, and J. B. Harford.
1994.
Evidence that the pathway of transferrin receptor mRNA degradation involves an endonucleolytic cleavage within the 3' UTR and does not involve poly(A) tail shortening.
EMBO J.
13:1969-1980[Medline].
|
| 4.
|
Binder, R.,
S. P. Hwang,
R. Ratnasabapathy, and D. L. Williams.
1989.
Degradation of apolipoprotein II mRNA occurs via endonucleolytic cleavage at 5'-AAU-3'/5'-UAA-3' elements in single-stranded loop domains of the 3'-noncoding region.
J. Biol. Chem.
264:16910-16918[Abstract/Free Full Text].
|
| 5.
|
Brewer, G.
1991.
An A + U-rich element RNA-binding factor regulates c-myc mRNA stability in vitro.
Mol. Cell. Biol.
11:2460-2466[Abstract/Free Full Text].
|
| 6.
|
Brown, B. D., and R. M. Harland.
1990.
Endonucleolytic cleavage of a maternal homeo box mRNA in Xenopus oocytes.
Genes Dev.
4:1925-1935[Abstract/Free Full Text].
|
| 7.
|
Brown, B. D.,
I. D. Zipkin, and R. M. Harland.
1993.
Sequence-specific endonucleolytic cleavage and protection of mRNA in Xenopus and Drosophila.
Genes Dev.
7:1620-1631[Abstract/Free Full Text].
|
| 8.
|
Cavanaugh, V. J.,
L. G. Guidotti, and F. V. Chisari.
1998.
Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infections in transgenic mice.
J. Virol.
72:2630-2637[Abstract/Free Full Text].
|
| 9.
|
Chernokalskaya, E.,
R. Dompenciel, and D. R. Schoenberg.
1997.
Cleavage properties of an estrogen-regulated polysomal ribonuclease involved in the destabilization of albumin mRNA.
Nucleic Acids Res.
25:735-742[Abstract/Free Full Text].
|
| 10.
|
Chisari, F. V.
1997.
Cytotoxic T cells and viral hepatitis.
J. Clin. Investig.
99:1472-1477[Medline].
|
| 11.
|
Chisari, F. V.,
C. A. Pinkert,
D. R. Milich,
P. Filippi,
A. McLachlan,
R. D. Palmiter, and R. L. Brinster.
1985.
A transgenic mouse model of the chronic hepatitis B surface antigen carrier state.
Science
230:1157-1160[Abstract/Free Full Text].
|
| 12.
|
Claverie-Martin, F.,
M. Wang, and S. N. Cohen.
1997.
ARD-1 cDNA from human cells encodes a site-specific single-strand endoribonuclease that functionally resembles Escherichia coli RNase E.
J. Biol. Chem.
272:13823-13828[Abstract/Free Full Text].
|
| 13.
|
Cunningham, K. S.,
R. E. Dodson,
M. A. Nagel,
D. J. Shapiro, and D. R. Schoenberg.
2000.
Vigilin binding selectively inhibits cleavage of the vitellogenin mRNA 3'-untranslated region by the mRNA endonuclease polysomal ribonuclease 1.
Proc. Natl. Acad. Sci. USA
97:12498-12502[Abstract/Free Full Text].
|
| 14.
|
Decker, C. J., and R. Parker.
1994.
Mechanisms of mRNA degradation in eukaryotes.
Trends Biochem. Sci.
19:336-340[CrossRef][Medline].
|
| 15.
|
Dompenciel, R. E.,
V. R. Garnepudi, and D. R. Schoenberg.
1995.
Purification and characterization of an estrogen-regulated Xenopus liver polysomal nuclease involved in the selective destabilization of albumin mRNA.
J. Biol. Chem.
270:6108-6118[Abstract/Free Full Text].
|
| 16.
|
Dong, B., and R. H. Silverman.
1997.
A bipartite model of 2-5A-dependent RNase L.
J. Biol. Chem.
272:22236-22242[Abstract/Free Full Text].
|
| 17.
|
Eisenstein, R. S.,
P. T. Tuazon,
K. L. Schalinske,
S. A. Anderson, and J. A. Traugh.
1993.
Iron-responsive element-binding protein. Phosphorylation by protein kinase C.
J. Biol. Chem.
268:27363-27370[Abstract/Free Full Text].
|
| 18.
|
Galibert, F.,
E. Mandart,
F. Fitoussi,
P. Tiollais, and P. Charnay.
1979.
Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli.
Nature
281:646-650[CrossRef][Medline].
|
| 19.
|
Gorlich, D., and U. Kutay.
1999.
Transport between the cell nucleus and the cytoplasm.
Annu. Rev. Cell Dev. Biol.
15:607-660[CrossRef][Medline].
|
| 20.
|
Guidotti, L. G.,
K. Ando,
M. V. Hobbs,
T. Ishikawa,
L. Runkel,
R. D. Schreiber, and F. V. Chisari.
1994.
Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice.
Proc. Natl. Acad. Sci. USA
91:3764-3768[Abstract/Free Full Text].
|
| 21.
|
Guidotti, L. G.,
P. Borrow,
M. V. Hobbs,
B. Matzke,
I. Gresser,
M. B. Oldstone, and F. V. Chisari.
1996.
Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver.
Proc. Natl. Acad. Sci. USA
93:4589-4594[Abstract/Free Full Text].
|
| 22.
|
Guidotti, L. G., and F. V. Chisari.
2000.
Cytokine-mediated control of viral infections.
Virology
273:221-227[CrossRef][Medline].
|
| 23.
|
Guidotti, L. G., and F. V. Chisari.
1996.
To kill or to cure: options in host defense against viral infection.
Curr. Opin. Immunol.
8:478-483[CrossRef][Medline].
|
| 24.
|
Guidotti, L. G.,
T. Ishikawa,
M. V. Hobbs,
B. Matzke,
R. Schreiber, and F. V. Chisari.
1996.
Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes.
Immunity
4:25-36[CrossRef][Medline].
|
| 25.
|
Guidotti, L. G.,
B. Matzke,
H. Schaller, and F. V. Chisari.
1995.
High-level hepatitis B virus replication in transgenic mice.
J. Virol.
69:6158-6169[Abstract].
|
| 26.
|
Heise, T.,
L. G. Guidotti,
V. J. Cavanaugh, and F. V. Chisari.
1999.
Hepatitis B virus RNA-binding proteins associated with cytokine-induced clearance of viral RNA from the liver of transgenic mice.
J. Virol.
73:474-481[Abstract/Free Full Text].
|
| 27.
|
Heise, T.,
L. G. Guidotti, and F. V. Chisari.
1999.
La autoantigen specifically recognizes a predicted stem-loop in hepatitis B virus RNA.
J. Virol.
73:5767-5776[Abstract/Free Full Text].
|
| 28.
|
Heise, T.,
A. Krones,
A. Nath,
K. Jungermann, and B. Christ.
1998.
Parallel acceleration of phosphoenolpyruvate carboxykinase mRNA degradation and increase in ribonuclease activity induced by insulin in cultured rat hepatocytes.
Biol. Chem. Hoppe-Seyler
379:875-883.
|
| 29.
|
Heise, T.,
A. Nath,
K. Jungermann, and B. Christ.
1997.
Purification of a RNA-binding protein from rat liver. Identification as ferritin L chain and determination of the RNA/protein binding characteristics.
J. Biol. Chem.
272:20222-20229[Abstract/Free Full Text].
|
| 30.
|
Hentze, M. W., and L. C. Kuhn.
1996.
Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress.
Proc. Natl. Acad. Sci. USA
93:8175-8182[Abstract/Free Full Text].
|
| 31.
|
Hua, J.,
R. Garner, and V. Paetkau.
1993.
An RNasin-resistant ribonuclease selective for interleukin 2 mRNA.
Nucleic Acids Res.
21:155-162[Abstract/Free Full Text].
|
| 32.
|
Kramer, A.
1996.
The structure and function of proteins involved in mammalian pre-mRNA splicing.
Annu. Rev. Biochem.
65:367-409[CrossRef][Medline].
|
| 33.
|
Lee, C. H.,
P. Leeds, and J. Ross.
1998.
Purification and characterization of a polysome-associated endoribonuclease that degrades c-myc mRNA in vitro.
J. Biol. Chem.
273:25261-25271[Abstract/Free Full Text].
|
| 34.
|
Li, X. L.,
J. A. Blackford, and B. A. Hassel.
1998.
RNase L mediates the antiviral effect of interferon through a selective reduction in viral RNA during encephalomyocarditis virus infection.
J. Virol.
72:2752-2759[Abstract/Free Full Text].
|
| 35.
|
Meinsma, D.,
P. E. Holthuizen,
J. L. Van den Brande, and J. S. Sussenbach.
1991.
Specific endonucleolytic cleavage of IGF-II mRNAs.
Biochem. Biophys. Res. Commun.
179:1509-1516[CrossRef][Medline].
|
| 36.
|
Melefors, O., and M. W. Hentze.
1993.
Iron regulatory factor the conductor of cellular iron regulation.
Blood Rev.
7:251-258[CrossRef][Medline].
|
| 37.
|
Moriyama, T.,
S. Guilhot,
K. Klopchin,
B. Moss,
C. A. Pinkert,
R. D. Palmiter,
R. L. Brinster,
O. Kanagawa, and F. V. Chisari.
1990.
Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice.
Science
248:361-364[Abstract/Free Full Text].
|
| 38.
|
Nielsen, F. C., and J. Christiansen.
1992.
Endonucleolysis in the turnover of insulin-like growth factor II mRNA.
J. Biol. Chem.
267:19404-19411[Abstract/Free Full Text].
|
| 39.
|
Nielsen, F. C., and J. Christiansen.
1995.
Posttranscriptional regulation of insulin-like growth factor II mRNA.
Scand. J. Clin. Lab. Investig.
220(Suppl.):37-46.
|
| 40.
|
Oroskar, A. A., and G. S. Read.
1989.
Control of mRNA stability by the virion host shutoff function of herpes simplex virus.
J. Virol.
63:1897-1906[Abstract/Free Full Text].
|
| 41.
|
Pastori, R. L.,
J. E. Moskaitis, and D. R. Schoenberg.
1991.
Estrogen-induced ribonuclease activity in Xenopus liver.
Biochemistry
30:10490-10498[CrossRef][Medline].
|
| 42.
|
Ross, J.
1995.
mRNA stability in mammalian cells.
Microbiol. Rev.
59:423-450[Abstract/Free Full Text].
|
| 43.
|
Ross, J.,
G. Kobs,
G. Brewer, and S. W. Peltz.
1987.
Properties of the exonuclease activity that degrades H4 histone mRNA.
J. Biol. Chem.
262:9374-9381[Abstract/Free Full Text].
|
| 44.
|
Salehzada, T.,
M. Silhol,
B. Lebleu, and C. Bisbal.
1991.
Polyclonal antibodies against RNase L. Subcellular localization of this enzyme in mouse cells.
J. Biol. Chem.
266:5808-5813[Abstract/Free Full Text].
|
| 45.
|
Schaller, H., and M. Fischer.
1991.
Transcriptional control of hepadnavirus gene expression.
Curr. Top. Microbiol. Immunol.
168:21-39[Medline].
|
| 46.
|
Schoenberg, D. R., and K. S. Cunningham.
1999.
Characterization of mRNA endonucleases.
Methods
17:60-73[CrossRef][Medline].
|
| 47.
|
Shatkin, A. J., and J. L. Manley.
2000.
The ends of the affair: capping and polyadenylation.
Nat. Struct. Biol.
7:838-842[CrossRef][Medline].
|
| 48.
|
Staton, J. M.,
A. M. Thomson, and P. J. Leedman.
2000.
Hormonal regulation of mRNA stability and RNA-protein interactions in the pituitary.
J. Mol. Endocrinol.
25:17-34[Abstract].
|
| 49.
|
Tsui, L. V.,
L. G. Guidotti,
T. Ishikawa, and F. V. Chisari.
1995.
Posttranscriptional clearance of hepatitis B virus RNA by cytotoxic T lymphocyte-activated hepatocytes.
Proc. Natl. Acad. Sci. USA
92:12398-12402[Abstract/Free Full Text].
|
| 50.
|
Wahle, E., and U. Ruegsegger.
1999.
3'-End processing of pre-mRNA in eukaryotes.
FEMS Microbiol. Rev.
23:277-295[Medline].
|
| 51.
|
Walter, A. E.,
D. H. Turner,
J. Kim,
M. H. Lyttle,
P. Muller,
D. H. Mathews, and M. Zuker.
1994.
Coaxial stacking of helixes enhances binding of oligoribonucleotides and improves predictions of RNA folding.
Proc. Natl. Acad. Sci. USA
91:9218-9222[Abstract/Free Full Text].
|
| 52.
|
Wang, M., and S. N. Cohen.
1994.
ard-1: a human gene that reverses the effects of temperature-sensitive and deletion mutations in the Escherichia coli rne gene and encodes an activity producing RNase E-like cleavages.
Proc. Natl. Acad. Sci. USA
91:10591-10595[Abstract/Free Full Text].
|
| 53.
|
Wang, Z., and M. Kiledjian.
2000.
Identification of an erythroid-enriched endoribonuclease activity involved in specific mRNA cleavage.
EMBO J.
19:295-305[CrossRef][Medline].
|
| 54.
|
Wang, Z., and M. Kiledjian.
2000.
The poly(A)-binding protein and an mRNA stability protein jointly regulate an endoribonuclease activity.
Mol. Cell. Biol.
20:6334-6341[Abstract/Free Full Text].
|
| 55.
|
Wennborg, A.,
B. Sohlberg,
D. Angerer,
G. Klein, and A. von Gabain.
1995.
A human RNase E-like activity that cleaves RNA sequences involved in mRNA stability control.
Proc. Natl. Acad. Sci. USA
92:7322-7326[Abstract/Free Full Text].
|
Journal of Virology, August 2001, p. 6874-6883, Vol. 75, No. 15
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.15.6874-6883.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Barnes, T., Kim, W.-C., Mantha, A. K., Kim, S.-E., Izumi, T., Mitra, S., Lee, C. H.
(2009). Identification of Apurinic/apyrimidinic endonuclease 1 (APE1) as the endoribonuclease that cleaves c-myc mRNA. Nucleic Acids Res
0: gkp275v1-gkp275
[Abstract]
[Full Text]
-
Glebe, D., Lorenz, H., Gerlich, W. H., Butler, S. D., Tochkov, I. A., Tennant, B. C., Cote, P., Menne, S.
(2009). Correlation of Virus and Host Response Markers with Circulating Immune Complexes during Acute and Chronic Woodchuck Hepatitis Virus Infection. J. Virol.
83: 1579-1591
[Abstract]
[Full Text]
-
Bitko, V., Musiyenko, A., Bayfield, M. A., Maraia, R. J., Barik, S.
(2008). Cellular La Protein Shields Nonsegmented Negative-Strand RNA Viral Leader RNA from RIG-I and Enhances Virus Growth by Diverse Mechanisms. J. Virol.
82: 7977-7987
[Abstract]
[Full Text]
-
Wieland, S. F., Chisari, F. V.
(2005). Stealth and Cunning: Hepatitis B and Hepatitis C Viruses. J. Virol.
79: 9369-9380
[Full Text]
-
Ehlers, I., Horke, S., Reumann, K., Rang, A., Grosse, F., Will, H., Heise, T.
(2004). Functional Characterization of the Interaction between Human La and Hepatitis B Virus RNA. J. Biol. Chem.
279: 43437-43447
[Abstract]
[Full Text]
-
Horke, S., Reumann, K., Rang, A., Heise, T.
(2002). Molecular Characterization of the Human La Protein{middle dot}Hepatitis B Virus RNA.B Interaction in Vitro. J. Biol. Chem.
277: 34949-34958
[Abstract]
[Full Text]
-
Sciortino, M. T., Taddeo, B., Poon, A. P. W., Mastino, A., Roizman, B.
(2002). Of the three tegument proteins that package mRNA in herpes simplex virions, one (VP22) transports the mRNA to uninfected cells for expression prior to viral infection. Proc. Natl. Acad. Sci. USA
99: 8318-8323
[Abstract]
[Full Text]
-
Rodgers, N. D., Wang, Z., Kiledjian, M.
(2002). Characterization and Purification of a Mammalian Endoribonuclease Specific for the alpha -Globin mRNA. J. Biol. Chem.
277: 2597-2604
[Abstract]
[Full Text]